Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?The Motley Fool • 08/10/26
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's ZepboundThe Motley Fool • 08/07/26
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost CutsZacks Investment Research • 08/05/26
Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/04/26
Pfizer Ducks Continued Covid Fallout As Hard-Fought Obesity Readout LoomsInvestors Business Daily • 08/04/26
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid productsCNBC • 08/04/26
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue GuidanceBusiness Wire • 08/04/26
Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga • 08/04/26
Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield?The Motley Fool • 08/03/26
Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?The Motley Fool • 07/31/26